U.K.'s National Institute for Health and Care Excellence has delivered a blow to Johnson & Johnson's Zytiga in final draft guidance recommending against the prostate cancer pill as a treatment for prostate cancer before chemotherapy. And nobody seems very happy about it--including NICE itself.
Like many medical device companies, Johnson & Johnson is waging patent battles on many fronts at once. Recently, two cases in which J&J was the defendant took interesting twists.
South Korea's Celltrion is aiming to be second in line when biosimilars make their U.S. landfall, filing an FDA application to market a knockoff of Johnson & Johnson's blockbuster Remicade.
Johnson & Johnson's canagliflozin was the first to win FDA approval among a new class of diabetes therapies, and now it's the star of the first such combination therapy to pass agency muster, helping the drug stand out in an increasingly cluttered market.
A Securities and Exchange Commission filing from Aug. 6 disclosed that Boston Scientific received a subpoena from the U.S. Attorney for the District of New Jersey regarding its acquisition of Bridgepoint Medical, leading to a sharp decline in trading.
Under pressure from consumer groups, Johnson & Johnson vowed to remove certain controversial ingredients from its baby and infant products two years ago. Now, the company is taking that oath and turning it into a marketing advantage.
Days after Johnson & Johnson pulled its devices for minimally invasive hysterectomies from the global market, physicians are shedding light on alternative surgical methods and questioning the recall's implications for women undergoing the procedure.
Amid regulatory and industry backlash surrounding the use of laparoscopic surgical tools in gynecological procedures, Johnson & Johnson is pulling its related device from the global market.
Spinal device specialist NuVasive said it's third in the spinal device market and is aiming now for second place along with more than $1 billion in annual revenue. Wall Street ate up that news, along with an earnings beat and raised guidance, and chased the stock up 10% in early trading on June 30.
Johnson & Johnson's new blood cancer drug Imbruvica (ibrutinib) is on a roll. The FDA just armed the drug with a new indication in chronic lymphocytic leukemia, adding to a series of regulatory nods.